SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Ligand (LGND) Breakout!
LGND 206.84+2.8%3:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: tonyt who wrote (20513)5/11/1998 8:48:00 PM
From: squetch  Read Replies (3) of 32384
 
Huh? Here is what SRGN lists as side-effects. Bear in mind 37% withdrawal b/c of adverse events The last line doesn't instill confidence in me.
>>Adverse Events Associated with Clinical Trials of Fusion Proteins

In all clinical trials of Seragen's fusion proteins described in this document, and as commonly noted during investigation of and treatment with most, if not all, biological agents, adverse events associated with administration of the particular fusion protein under investigation did occur.
These events included, but were not limited to, flu-like symptoms, rash, and transient elevation of liver enzyme (transaminase) levels. Some patients have experienced adverse events requiring hospitalization. These adverse events included problems associated with the patients' underlying disease as well as those associated with treatment. In some cases, patients experiencing adverse events discontinued participation in the trial.

Further testing in a larger number of patients is required to determine the safety and effectiveness of Seragen's fusion proteins in psoriasis, rheumatoid arthritis, HIV infection and solid tumor cancers. Further testing may also be required to determine the safety and effectiveness of DAB389IL-2 in CTCL.<<
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News